Vesugen vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
VesugenFat Loss & Metabolic
5-Amino-1MQ- Summary
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Estimated 4–8 hours
- Admin Route
- SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 50–100 mg
- Frequency
- Daily for 10–30 days
- Once to twice daily
- Key Benefits
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —